| Last Price | Today's Change | 52-Week Range | Trading Volume |
|---|---|---|---|
| 0.93 | -0.05 (-5.17%) | 0.75 - 9.44 | 871.9 thousand (Above Avg) |
Market data as of 10:37AM 05/21/13. Quotes are delayed by at least 15 min.
| Open | 0.99 |
|---|---|
| Previous Close | 0.98 |
| Day's Range | 0.92 - 0.99 |
| Market Cap | 48.0M |
| Avg Volume (10 Day) | 2.8M |
| Price/Earnings (Trailing 12 Mo.) | 1.3x |
| Earnings Per Share (Trailing 12 Mo.) | 2.79 |
| Dividend Yield | No Dividend |


These seven metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Performed well consistently? | Fail |
|---|---|
| Avoids excess debt? | Fail |
| Converting sales to profits? | Fail |
| Shareholder's money handled rationally? | Neutral |
| Increased shareholder value? | Neutral |
| Consistently increased owner earnings? | Fail |
| Sells at 25% discount to intrinsic value? | Fail |


These eight metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Pays a cash dividend? | Fail |
|---|---|
| Room to increase dividends? | Fail |
| Increased earnings over time? | Fail |
| Borrows within reasonable limits? | Pass |
| Stock is undervalued? | Fail |
| Have investors caught on? | Fail |
| Has support of institutional investors? | Fail |
| Has sufficient liquidity? | Pass |
Celsion's ThermoDox® HEAT Study Findings Reviewed at the 9th Annual World Conference on Interventional Oncology (WCIO)
PR Newswire - Friday 05/17/2013 8:00 AM ET
Celsion Corporation Reports First Quarter 2013 Financial Results and Provides Business Update
PR Newswire - Thursday 05/09/2013 8:00 AM ET
Celsion Corporation to Hold First Quarter 2013 Financial Results Conference Call on Thursday, May 9, 2013
PR Newswire - Wednesday 05/01/2013 8:00 AM ET
Celsion Announces ThermoDox® HEAT Study Findings to be Reviewed at the 9th Annual World Conference on Interventional Oncology (WCIO) in New York City on May 16, 2013
PR Newswire - Wednesday 05/01/2013 8:00 AM ET
Celsion Corporation Provides Business Update
PR Newswire - Tuesday 04/23/2013 8:00 AM ET
| CLSN | Industry Range | |
|---|---|---|
| Revenue Growth (1yr) | -- | |
| Net Income Growth (1yr) | -- | |
| Total Debt/Equity | 0.16 | |
| LT Debt/Equity | 0.10 | |
| Earnings Yield | 76.92% | |
| Price/Sales | 404.65 |
| Company | Last | Change |
|---|---|---|
| EntreMed Inc | 1.84 | -0.81% |
| AEterna Zentaris Inc | 2.05 | -0.49% |
| Affymax Inc | 1.34 | +5.50% |
| Transcept Pharmaceuticals Inc | 3.20 | +1.27% |
| Savient Pharmaceuticals Inc | 0.58 | +4.31% |
Data is delayed by at least 15 min.